Posted in | Nanomedicine | Nanobusiness

Spectrum Pharmaceuticals Starts Phase I Study of Nanotechnology Compound, RenaZorb

Spectrum Pharmaceuticals has started patient enrollment for a Phase I clinical study to assess the tolerability and safety of a lanthanum-based nanotechnology compound named RenaZorb, which has strong phosphate-binding properties.

The Phase 1 study of RenaZorb is a double-blind, dose-ranging trial in healthy volunteers to assess the phosphate-binding capacity and safety of the lanthanum-based nanotechnology compound. The main endpoint of the study is to evaluate the phosphorous-binding capacity by comparing the variation in phosphorus levels in fecal and urine prior to and after the dosing of RenaZorb.

Other endpoints of the trial are to evaluate the tolerability and safety of RenaZorb and to measure serum lanthanum levels. Thirty two healthy volunteers are expected to participate in the study, which will comprise four sequential dose cohorts with eight subjects each. Six subjects will receive RenaZorb arbitrarily and remaining two subjects will get placebo.

All four cohorts, which include 6000 mg/day, 4500 mg/day, 3000 mg/day and 1500 mg/day), will take RenaZorb orally three times in a day inside 15 minutes after consuming meals. Following the dosing of RenaZorb, it is anticipated that phosphate fecal excretion will increase and phosphate renal excretion rate will decrease.

Spectrum Pharmaceuticals’ Chairman, President and Chief Executive Officer, Rajesh C. Shrotriya stated that the company is happy to start RenaZorb’s first human clinical trial on the basis of prior positive results. In vitro study demonstrated the superior phosphate-binding capacity of RenaZorb. The company expects that it can offer the same level of phosphate-binding capacity at a smaller tablet size and lower dose, thus enhancing patient tolerability.

Source: http://www.sppirx.com/

Will Soutter

Written by

Will Soutter

Will has a B.Sc. in Chemistry from the University of Durham, and a M.Sc. in Green Chemistry from the University of York. Naturally, Will is our resident Chemistry expert but, a love of science and the internet makes Will the all-rounder of the team. In his spare time Will likes to play the drums, cook and brew cider.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Soutter, Will. (2019, February 12). Spectrum Pharmaceuticals Starts Phase I Study of Nanotechnology Compound, RenaZorb. AZoNano. Retrieved on June 02, 2020 from https://www.azonano.com/news.aspx?newsID=24941.

  • MLA

    Soutter, Will. "Spectrum Pharmaceuticals Starts Phase I Study of Nanotechnology Compound, RenaZorb". AZoNano. 02 June 2020. <https://www.azonano.com/news.aspx?newsID=24941>.

  • Chicago

    Soutter, Will. "Spectrum Pharmaceuticals Starts Phase I Study of Nanotechnology Compound, RenaZorb". AZoNano. https://www.azonano.com/news.aspx?newsID=24941. (accessed June 02, 2020).

  • Harvard

    Soutter, Will. 2019. Spectrum Pharmaceuticals Starts Phase I Study of Nanotechnology Compound, RenaZorb. AZoNano, viewed 02 June 2020, https://www.azonano.com/news.aspx?newsID=24941.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit